The largest database of trusted experimental protocols

12 protocols using mrt68921

1

Mitophagy Induction and ATG9A Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
For translocation and mitophagy experiments, cells were either left untreated or treated with 10 mM Oligomycin (Calbiochem), 4 mM Antimycin A (Sigma) and 5 mM QVD (MedChemExpress) in full growth medium for different time points as indicated in figure legends. Long treatment time point samples were treated with 10 mM QVD instead of 5 mM. For starvation experiments, cells were fed in full medium for 1 h prior to 8 h starvation using Earle's Balanced Salt Solution (EBSS; Life Technologies). For the analysis of ATG9A (Figures 5A, 5D, S6A, and S6B), indicated samples were pre-treated for 30 min with 1 mM MRT68921 (Selleck Chemicals) before inducing mitophagy in the presence of 1 mM MRT68921.
+ Open protocol
+ Expand
2

Phospho-p38α and Phospho-MKK4 Antibody Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against phospho-p38α (Thr180/Tyr182) (Cat# 4511S) and phospho-MKK4 (Ser257) (Cat# 4514S) were purchased from Cell Signaling Technologies (Beverly, MA, USA). Antibodies against MKK4 (Cat# A14781) were from ABclonal Technology (Wuhan, China). Antibody against p38 (Cat# sc-81621) was from Santa Cruz biotechnology (Santa Cruz, CA, USA). Antibody against GAPDH (Cat# 60004-1-Ig) was from Proteintech Group (Chicago, IA, USA). Tubeimoside-2 was purchased from Chengdu Biopurify Phytochemicals Ltd. (Chengdu, China). Small-molecular inhibitor MRT68921 (Cat# S7949) was from Selleck Chemicals(Houston, TX, USA); other small molecular inhibitors, 3-methyladenine (Cat# HY-19312), Wortmannin (Cat# HY-10197), EIPA (Cat# HY-101840), PD 169,316 (Cat# HY-10578), EHop-016 (Cat# HY-12810), and EHT 1864 (Cat# HY-16659) were purchased from MedChemExpress (MCE, Shanghai, China). We purchased 70 kDa dextran (Cat# D1818) and lucifer yellow (#L1177) from Life Technologies (Waltham, MA, USA). All reagents unless otherwise stated were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
+ Open protocol
+ Expand
3

Autophagy Modulation with Pharmacological Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Stock solutions of reagents were prepared by dissolving the reagents in dimethyl sulfoxide (DMSO, Sigma-Aldrich). SBI-0206965, GSK 2606414, and MRT 68921 were purchased from Selleck Chemicals (Houston, TX, USA). Bafilomycin A1 and 3-methyladenine (3-MA) were purchased from Sigma-Aldrich. Hydroxychloroquine (HCQ) was purchased from Myung-in Pharmaceuticals. z-VAD-FMK was obtained from R&D Systems. Control cells were treated with equal amounts of DMSO.
+ Open protocol
+ Expand
4

Glioblastoma Cell Culture Optimization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Reagents included torin2 and rapamycin (both Sigma-Aldrich, St. Louis, MO, USA), bafilomycin A1 (Cayman Chemicals, Ann Arbor, MI, USA) and MRT68921 (Selleck Chemicals, Houston, TX, USA). LN-229 were purchased from ATCC (Manassas, Virginia, USA). LN-308 cells were a kind gift from Prof. Nicolas de Tribolet (Lausanne, Switzerland) and were recently authenticated by short tandem repeat (STR) profiling. Cells were maintained at 37 °C and 5% CO2 using Dulbecco’s modified eagle medium (DMEM). The medium was supplemented with 10% fetal calf serum (Biochrom KG, Berlin, Germany), 100 µg/mL streptomycin and 100 IU/mL penicillin (Life Technologies, Karlsruhe, Germany). Cells were tested regularly for mycoplasma infection. For starvation conditions, cells were incubated in serum-free medium with 2 mM glucose. For hypoxic experimental conditions of 0.1% oxygen, we used Gas Pak pouches (Becton-Dickinson, Heidelberg, Germany).
+ Open protocol
+ Expand
5

Cancer Cell Line Cultivation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human cancer cell lines A549, H1299, NCI-H460, MNK45, U251, SW480, SW620, HCT116, Colo320 and HT-29, PC-3, U266, and the mouse breast cancer cell line 4T1 were cryopreserved in the Hematological Laboratory of Zhujiang Hospital (Guangzhou, China). All cell lines were incubated in DMEM medium supplemented with 10% fetal bovine serum at 37 °C with 5% CO2. WZ4003, SBI-0206965, Chloroquine, and MRT68921 were purchased from Selleckchem (Houston, TX, USA), dissolved in DMSO or water, and stored at −20 °C. CCK-8 was purchased from Dojindo Laboratories (Japan). Mitotracker, DAPI, and TritonX-100 were purchased from Solarbio (Beijing, China).
+ Open protocol
+ Expand
6

Western Blot Antibody Validation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary antibodies used in Western blot studies included anti-LC3B antibody (#L7543, 1:1000) from Sigma-Aldrich (Burlington, MA, USA), anti-MYC (Y69, #ab32072, 1:1000) from Abcam (Cambridge, MA, USA), anti-ULK1 (D8H5, #8054, 1:1000) from Cell Signaling Technology (Danvers, MA, USA), anti-ULK2 (#PA5-22173, 1:1000) from ThermoFisher Scientific (Waltham, MA, USA), and anti-β-actin (#sc-47778, 1:2000) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). MRT68921 (#S7949), Ara-C (U-19920A, #S1648), and chloroquine (#S6999) were purchased from Selleckchem (Houston, TX, USA). IRDye 800CW goat anti-rabbit IgG (#926-32213, 1:40,000) and anti-mouse IgG (#926-32212, 1:40,000) were used as the secondary antibody (LI-COR Biosciences, Lincoln, NE, USA).
+ Open protocol
+ Expand
7

Autophagy Modulation by Small Molecules

Check if the same lab product or an alternative is used in the 5 most similar protocols
Forskolin, doxorubicin, propidium iodide (PI), paraformaldehyde (PFA), and 3-methyladenine (3-MA) were purchased from Sigma-Aldrich. 8-CPT-cAMP and RP-8-Br-cAMPS were from BioLog, and bafilomycin A1 (BafA1) was from AH Diagnostics. The ULK1 inhibitor MRT68921 was obtained from Selleckchem. Antibody against p53 (DO-1, # SC-126) was obtained from Santa Cruz Biotechnology. Anti-LC3B (# 2775) used for Western blot analyses was purchased from Cell Signaling Technology, whereas Anti-LC3B (# PM036) used for immunofluorescence analyses was obtained from MBL International. Antibodies against glyceralaldehyde 3-phosphate dehydrogenase (GAPDH) was purchased from Sigma Aldrich. As loading control in Western blot analyses we used an antibody directed against Calnexin (# 2433) from Cell Signaling Technology.
+ Open protocol
+ Expand
8

Lipid Reagents for Cellular Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
All lipids were purchased pre-dissolved in chloroform, except for PI(3)P, from Avanti Polar Lipids. Lipids used in Fig. 1 and Supplementary Fig. 1 are: L-α-phosphatidylethanolamine (840022C) (BrainPE), L-α-phosphatidylserine (840032C) (Brain PS) and L-α-phosphatidylcholine (840053C) (Brain PC). Lipids used in Fig. 2, 3 and 6 are: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (850725C) (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (810150C) (Rhod-PE), 1palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (850457C) (POPC), 1,2-dioleoyl-sn-glycero3-phospho-(1’-myo-inositol-3’-phosphate) (850150P) (PI(3)P) and L-α-phosphatidylinositol (Liver, Bovine) (840042C) (PI). Adenosine-5’-triphosphate (A2383, Sigma) (ATP), Bafilomycin A1 (BML-CM110, AH diagnostics) (BafA1), Deferiprone (379409, Sigma) (DFP), Fibronectin (F2006–1MG, Sigma), Hoechst 33342 (H1399, Thermo Fisher Scientific), Hygromycin b (400052–20), Monensin sodium salt (M5273, Sigma), MRT68921 (S7949, Selleckchem), Puromycin dihydrochloride (P7255, Sigma), VPS34-IN1 (S7980, Selleckchem), Zeocin (45–0430, Invitrogen), Zymosan A particles (Alexa 594 Z23374 and Alexa 488 Z23373, Thermo Fischer Scientific).
+ Open protocol
+ Expand
9

Combinatorial Drug Screening in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were plated in 96-well plates and exposed to AZD5991 (Chemietek Cat#CT-A5991 or Astrazeneca), AMG176 (MedChemExpress), AZD4320 (Astrazeneca), Venetoclax (Selleckchem), Azacytidine (Selleckchem), Venetoclax+Azacytidine (Ven:Aza = 1:4), Chloroquine (Sigma Aldrich, Cat#C6628) or ULK1i (MRT68921, Selleckchem, Cat#S7949) with a minimum of three technical replicates per concentration per cell line. Cell viability was measured with the CellTiter-Glo 2.0 reagent (Promega, Cat#G9243) according to manufacturer’s instructions. Absolute viability values were converted to percentage viability versus DMSO control treatment, and then non-linear fit of log(inhibitor) versus response (three parameters) was performed in GraphPad Prism v8.0 to obtain the IC50 values. For multi-drug combination profiling data, SynergyFinder (version 2.0) was used (https://synergyfinder.fimm.fi/). The expected drug combination responses were calculated based on ZIP reference model using SynergyFinder83 (link). Deviations between observed and expected responses with positive and negative values denote synergy and antagonism respectively. For estimation of outlier measurements, cNMF algorithm84 (link) implemented in SynergyFinder was utilized.
+ Open protocol
+ Expand
10

Probing Signaling Pathways via Western Blot and IP

Check if the same lab product or an alternative is used in the 5 most similar protocols
Western blotting was performed as described previously [63 (link)]. Briefly, cell or tissue samples were separated on SDS-polyacrylamide gel, transferred onto a nitrocellulose membrane, and probed with antibodies as indicated. Immunoprecipitation (IP) was performed as previously described [59 (link)]. RNA immunoprecipitation (RIP) was performed using Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Burlington, MA, USA) according to the manufacturer’s instructions. The following antibodies were used in this study: ATG7 (Proteintech, Wuhan, China), IRF3 (Cell Signaling Technology, Danvers, MA, USA), phospho-IRF3 (S386) (abcam, Cambridge, UK), P65 (Cell Signaling Technology, Danvers, MA, USA), phospho-P65 (S536) (Cell Signaling Technology, Danvers, MA, USA), and actin (Santa Cruz Biotechnology, Dallas, TX, USA). The antibody against IAV NP was generated and used as previously described [58 (link)]. The following reagents were used in this study: dimethyl sulfoxide (DMSO) (Sigma-Aldrich), hydroxychloroquine Sulfate (HCQ) (Selleck, Houston, TX, USA), and MRT68921 (Selleck).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!